Premium Phosphosite-Specific 7TM Antibodies
Your Resource for GPCR Research
Select Your Country of Delivery below

GPR30/GPER Antibodies

Close filters
No results were found for the filter!
Rabbit Monoclonal
NEW
GPER/GPR30 [UMB27] (RM-non-phospho-G Protein-Coupled Estrogen Receptor Antibody), Rabbit Monoclonal
GPER/GPR30 [UMB27] (RM-non-phospho-G...
The non-phospho-GPER/GPR30 antibody is directed against the distal end of the carboxyl-terminal tail of human GPER/GPR30. It can be used to detect total GPER/GPR30 receptors in Western blots independent of phosphorylation. The GPER/GPR30...
£ 495.00 *
Rabbit Monoclonal
NEW
GPER/GPR30 [UMB27] (RM-IHC-Grade-G Protein-Coupled Estrogen Receptor Antibody), Rabbit Monoclonal
GPER/GPR30 [UMB27] (RM-IHC-Grade-G...
The non-phospho-GPER/GPR30 antibody is directed against the distal end of the carboxyl-terminal tail of human GPER/GPR30. It can be used to detect total GPER/GPR30 receptors in Western blots independent of phosphorylation. The GPER/GPR30...
£ 495.00 *

The G protein-coupled estrogen receptor (GPER), formerly known as GPR30 and encoded by GPER1, is a class A receptor activated by 17β-estradiol. Depending on the cellular context, its activation can increase cAMP, mobilize intracellular calcium, and transactivate the epidermal growth factor receptor, engaging ERK and PI3K–AKT signaling. GPER is broadly expressed in reproductive tissues, the cardiovascular system, the central nervous system, and several immune cell populations. It has been detected at the plasma membrane and in intracellular compartments, particularly the endoplasmic reticulum. Experimental studies implicate GPER in vascular regulation, metabolism, inflammation, and cancer, with responses varying between tissues. Cell-surface GPER undergoes constitutive internalization and can be directed toward proteasomal degradation through a trans-Golgi-associated pathway. The synthetic agonist G-1 and antagonists G15 and G36 are widely used as experimental tools. The oral selective agonist LNS8801 has entered clinical trials as monotherapy and in combination with pembrolizumab for advanced cancers, including melanoma. No GPER-selective drug is currently approved for therapeutic use. For more information on CaS receptor pharmacology please refer to the IUPHAR database. For further reading refer to:

Davenport AP, Bonner TI, Foord SM, Harmar AJ, Neubig RR, Pin JP, Spedding M, Kojima M, Kangawa K. International Union of Pharmacology. LVI. Ghrelin receptor nomenclature, distribution, and function. Pharmacol Rev. 2005 Dec;57(4):541-6. doi: 10.1124/pr.57.4.1. PMID: 16382107.

Ge X, Yang H, Bednarek MA, Galon-Tilleman H, Chen P, Chen M, Lichtman JS, Wang Y, Dalmas O, Yin Y, Tian H, Jermutus L, Grimsby J, Rondinone CM, Konkar A, Kaplan DD. LEAP2 Is an Endogenous Antagonist of the Ghrelin Receptor. Cell Metab. 2018 Feb 6;27(2):461-469.e6. doi: 10.1016 j.cmet.2017.10.016. PMID: 29233536.

The G protein-coupled estrogen receptor (GPER), formerly known as GPR30 and encoded by GPER1 , is a class A receptor activated by 17β-estradiol. Depending on the cellular context, its activation... read more »
Close window
GPR30/GPER Antibodies

The G protein-coupled estrogen receptor (GPER), formerly known as GPR30 and encoded by GPER1, is a class A receptor activated by 17β-estradiol. Depending on the cellular context, its activation can increase cAMP, mobilize intracellular calcium, and transactivate the epidermal growth factor receptor, engaging ERK and PI3K–AKT signaling. GPER is broadly expressed in reproductive tissues, the cardiovascular system, the central nervous system, and several immune cell populations. It has been detected at the plasma membrane and in intracellular compartments, particularly the endoplasmic reticulum. Experimental studies implicate GPER in vascular regulation, metabolism, inflammation, and cancer, with responses varying between tissues. Cell-surface GPER undergoes constitutive internalization and can be directed toward proteasomal degradation through a trans-Golgi-associated pathway. The synthetic agonist G-1 and antagonists G15 and G36 are widely used as experimental tools. The oral selective agonist LNS8801 has entered clinical trials as monotherapy and in combination with pembrolizumab for advanced cancers, including melanoma. No GPER-selective drug is currently approved for therapeutic use. For more information on CaS receptor pharmacology please refer to the IUPHAR database. For further reading refer to:

Davenport AP, Bonner TI, Foord SM, Harmar AJ, Neubig RR, Pin JP, Spedding M, Kojima M, Kangawa K. International Union of Pharmacology. LVI. Ghrelin receptor nomenclature, distribution, and function. Pharmacol Rev. 2005 Dec;57(4):541-6. doi: 10.1124/pr.57.4.1. PMID: 16382107.

Ge X, Yang H, Bednarek MA, Galon-Tilleman H, Chen P, Chen M, Lichtman JS, Wang Y, Dalmas O, Yin Y, Tian H, Jermutus L, Grimsby J, Rondinone CM, Konkar A, Kaplan DD. LEAP2 Is an Endogenous Antagonist of the Ghrelin Receptor. Cell Metab. 2018 Feb 6;27(2):461-469.e6. doi: 10.1016 j.cmet.2017.10.016. PMID: 29233536.

Recently viewed